Overview
Spherix’s coverage of the chronic kidney disease market monitors the dynamic and evolving landscape of CKD non-dialysis patient management. We closely track the competitive hyperkalemia market, along with the rapidly evolving diabetic kidney disease market, with specific deep-dives into SGLT2 inhibitors and their potential seismic market impacts. This research also delves into other disease states impacting CKD non-dialysis patients, such as metabolic acidosis and hypertension.
Services Available
Trending market evolution
Chronic Kidney Disease (US) – Diabetic Kidney Disease, Hyperkalemia, Hypertension, and Metabolic Acidosis - quarterly, n=100
Exploring the patient journey
Chronic Kidney Disease, Non-Dialysis (US) - n=1,000 patient charts
Chronic Kidney Disease, Non-Dialysis – PCP Perspective (US) - n=1,000 patient charts
Dialysis (US) - n=1,000 patient charts
Incident Dialysis (US) - n=650 patient charts
Prepping for the pipeline
Metabolic Acidosis (US)
Uremic Pruritus (US)
Gauging impact of disruptive events
Evolution of SGLT2 Inhibitors in DKD and Beyond
Multi-Specialty Impact of COVID-19 (US)